Completed PHASE4 INTERVENTIONAL 1-arm NCT00598897

Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease

Open, Noncomparative Trial of Multidrug Regimens Containing Clarithromycin and Rifabutin Administered Three Times Per Week for the Treatment of M. Avium Complex (MAC) Lung Disease

Sponsor: Abbott

Conditions Mycobacterium Avium Complex Lung Disease

Interventions clarithromycin, rifabutin

Updated 7 times since 2017 Last updated: May 19, 2017 Started: Aug 31, 1995 Primary completion: Aug 7, 2002 Completion: May 18, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Mycobacterium Avium Complex Lung Disease, this trial is completed. The trial is conducted by Abbott and has accumulated 7 data snapshots since 1995. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jul 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Unknown Status → Completed

▶ Show 2 earlier versions

Feb 2017 — Jul 2017 [monthly]

Unknown Status PHASE4
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE4

First recorded

Aug 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
Pfizer
The University of Texas Health Science Center at Tyler

Data source: The University of Texas Health Science Center at Tyler

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tyler, United States